ClinicalTrials.gov
public full text
Public Domain
Colchicine in Moderate Symptomatic COVID-19 Patients
This is a prospective, double blind, randomized, placebo controlled clinical trial. The participants will be randomized into two groups (group A and group B). Patients of group-A are the treatment group. They will be treated with optimal treatment based on the algorithm proposed in National Guidelines on Clinical Management of Coronavirus Disease 2019 (Covid-19) Version 7.0, 28 May 2020, along with Colchicine for 14 days. The patients in group-B will be controlled group. They will be treated with optimal treatment based on the algorithm proposed in National Guideline along with a placebo.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19#847382
- Piclidenoson for Treatment of COVID-19#1165253
- Ain Shams University Experience: Clinical Determinants of Hospitalized COVID-19 Patients#1047406
- Colchicine in Patients with Chronic Coronary Disease#315174
- RDW, Platelet Kinetics and Survival Outcome in Covid-19 Hospitalized Patients.#883201
Record · ID 834284
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive